# Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma

> **NCT03086174** · PHASE1 · UNKNOWN · sponsor: **Shanghai Junshi Bioscience Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Kidney Cancer Stage Iv
- Advanced Melanoma

## Interventions

- **BIOLOGICAL:** humanized anti-PD-1 monoclonal antibody Toripalimab

## Key facts

- **NCT ID:** NCT03086174
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-31
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03086174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03086174, "Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03086174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*